Indian stocks: Visit www.stage2stocks.com →

Talphera, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Talphera is in Stage 3, the topping phase, now in week 4 (since Sep 30, 2026). It closed at $1.05, 28.6% below its 52-week high and above its 200-day average, which is falling.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More about the company

$1.05
-1.87% today
$54.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is TLPH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S3 14w
S4 42w
S2 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 16w → S1 7w → S2 12w → S3 14w → S4 5w → S1 3w → S4 5w → S1 1w → S4 42w → S1 2w → S2 16w → S3 11w → S4 11w → S1 5w → S2 10w → S3 3w current
Total tracked: 164 weeks across 17 stage runs.

TLPH among Drug Manufacturers - Specialty & Generic35th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…35TLPHStage 3 · wk 448−9.5%
vs 52W High
-28.6%
$0.72 lo$1.47 hi
28.6% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 4
1w13w26w
Week 4, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
3.8%
200 DMA: $1.01 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.20x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-9.5%
3M
-22.2%
6M
+31.3%
YTD
-9.5%
1Y
-7.1%
Scan Membership
Breakout Watch
Latest: 2024-02-07
5 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 4 · Vol 0.20x
2026-10-21S3
Wk 4 · Vol 0.19x
2026-10-20S3
Wk 3 · Vol 0.10x
2026-10-19S3
Wk 3 · Vol 0.16x
2026-10-16S3
Wk 3 · Vol 0.20x
2026-10-15S3
Wk 3 · Vol 0.17x
2026-10-14S3
Wk 3 · Vol 0.24x
2026-10-13S3
Wk 2 · Vol 0.30x
2026-10-12S3
Wk 2 · Vol 0.12x
2026-10-09S3
Wk 2 · Vol 0.30x
2026-10-08S3
Wk 2 · Vol 1.15x
2026-10-07S3
Wk 2 · Vol 1.29x
Moving averages & range
50 DMA
$1.16
200 DMA
$1.01
52W High
$1.47
52W Low
$0.72
5D Low
$1.05
Resistance levels (recent highs)
20d High
$1.19
60d High
$1.47
120d High
$1.47
250d High
$1.47
Next resistance
+13.3%
to 20d High
ROE
-143.4%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.8

Talphera: quick answers

What stage is Talphera in?

As of Oct 22, 2026, Talphera (TLPH) is in Stage 3, the topping phase. It entered Stage 3 on Sep 30, 2026 and is in week 4. What the four stages mean

Is Talphera in an uptrend?

Its uptrend has stalled. Talphera is in Stage 3, the topping phase that follows an advance. It trades 3.8% above its 200-day average, which is falling.

How far is Talphera from its 52-week high?

Talphera closed at $1.05 on Oct 22, 2026, 28.6% below its 52-week high of $1.47. Its 52-week low is $0.72.

How has Talphera performed over the past year?

As of Oct 22, 2026, Talphera is down 7.1% over the past year and down 9.5% so far in 2026.

Which sector and industry is Talphera in?

Talphera is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.